TG Therapeutics TGTX
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
Key Insights
TG Therapeutics (TGTX) Core Market Data and Business Metrics
Latest Closing Price
$37.75Price-Earnings Ratio
251.67Total Outstanding Shares
155.67 Million SharesDividend
No dividendSIC Description
Pharmaceutical PreparationsPrimary Exchange
NASDAQHeadquarters
2 Gansevoort Street, 9th Floor, New York, NY, 10014
Historical Stock Splits
If you bought 56.25 shares of TGTX before April 30, 2012, you'd have 1 share today.
| Execution Date | Split Amount |
|---|---|
| April 30, 2012 | 1-for-56.25 (Reverse Split) |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Investing Activities | $-1.04 Million |
| Net Cash Flow From Financing Activities | $128.53 Million |
| Net Cash Flow, Continuing | $86.97 Million |
| Net Cash Flow From Investing Activities, Continuing | $-1.04 Million |
| Net Cash Flow | $86.97 Million |
| Net Cash Flow From Operating Activities | $-40.52 Million |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Income/Loss From Continuing Operations Before Tax | $25.59 Million |
| Gross Profit | $290.52 Million |
| Costs And Expenses | $287.07 Million |
| Net Income/Loss Attributable To Noncontrolling Interest | $0 |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0 |
| Cost Of Revenue | $38.49 Million |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss | $23.38 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Other Comprehensive Income/Loss | $0 |
| Comprehensive Income/Loss Attributable To Parent | $23.38 Million |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Cash | $311 Million |
| Liabilities And Equity | $577.69 Million |
| Other Current Assets | $144.90 Million |
| Inventory | $110.46 Million |
| Equity Attributable To Parent | $222.36 Million |
| Assets | $577.69 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||